TY - JOUR T1 - Let the DOCTOR Decide Whom to Test: Adaptive Testing Strategies to Tackle the COVID-19 Pandemic JF - medRxiv DO - 10.1101/2020.12.18.20248498 SP - 2020.12.18.20248498 AU - Yu Liang AU - Amulya Yadav Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/22/2020.12.18.20248498.abstract N2 - A robust testing program is necessary for containing the spread of COVID-19 infections before a vaccine becomes available. However, due to an acute shortage of testing kits (especially in low-resource developing countries), designing an optimal testing program/strategy is a challenging problem to solve. Prior literature on testing strategies suffers from two major limitations: (i) it does not account for the trade-off between testing of symptomatic and asymptomatic individuals, and (ii) it primarily focuses on static testing strategies, which leads to significant shortcomings in the testing program’s effectiveness. In this paper, we address these limitations by making five novel contributions. (i) We formally define the optimal testing problem and propose the DOCTOR POMDP model to tackle it. (ii) We solve the DOCTOR POMDP using a scalable Monte Carlo tree search based algorithm. (iii) We provide a rigorous experimental analysis of DOCTOR’s testing strategies against static baselines - our results show that when applied to the city of Santiago in Panama, DOCTOR’s strategies result in ∼40% fewer COVID-19 infections (over one month) as compared to state-of-the-art static baselines. (iv) In addition, we analyze DOCTOR’s testing policy to derive insights about the reasons behind the optimality of DOCTOR’s testing policy. (v) Finally, we characterize conditions (of the real world) under which DOCTOR’s optimization would be of most benefit to government policy makers, and thus requires significant attention from researchers in this area. Our work complements the growing body of research on COVID-19, and serves as a proof-of-concept that illustrates the benefit of having an AI-driven adaptive testing strategy for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis paper is not related to clinical study.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approval needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPanama's COVID-19 infections number https://www.worldometers.info/coronavirus/country/panama/ ER -